ÂÜÀòÂÒÂ×

Russell Hanson serves as the Chief Innovation Officer at Sama Therapeutics, focusing on precision neuropsychiatry through AI and machine learning. In addition, Russell functions as an AI & Data Science Advisor at Superduper and provides advisory services at Equideum Health and Ligandal. Russell has held key positions as Chief Scientific Officer and Co-Founder at Aptavid, where significant advancements in AI and biomarker development were made, particularly in rapid COVID-19 testing. Previously, Russell was Chief Scientist at Augustus Intelligence, leading AI efforts for Fortune 500 companies, and served as Chief Scientific Officer at ConsenSys, specializing in AI for cryptocurrency. Russell's academic background includes various educational institutions and a role as Assistant Professor at the Icahn School of Medicine at Mount Sinai, concentrating on genomics and multiscale biology.